UY34114A - Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a - Google Patents

Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a

Info

Publication number
UY34114A
UY34114A UY0001034114A UY34114A UY34114A UY 34114 A UY34114 A UY 34114A UY 0001034114 A UY0001034114 A UY 0001034114A UY 34114 A UY34114 A UY 34114A UY 34114 A UY34114 A UY 34114A
Authority
UY
Uruguay
Prior art keywords
inhibitors
quiinasa
aurora
combination
mek
Prior art date
Application number
UY0001034114A
Other languages
English (en)
Spanish (es)
Inventor
Chakravarty Arijit
Vincent Patrick
Original Assignee
Millennium Pharm Inc
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Takeda Pharmaceutical filed Critical Millennium Pharm Inc
Publication of UY34114A publication Critical patent/UY34114A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001034114A 2011-06-03 2012-06-01 Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a UY34114A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493217P 2011-06-03 2011-06-03
US201261613207P 2012-03-20 2012-03-20

Publications (1)

Publication Number Publication Date
UY34114A true UY34114A (es) 2013-01-03

Family

ID=47259953

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034114A UY34114A (es) 2011-06-03 2012-06-01 Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a

Country Status (9)

Country Link
US (1) US9629850B2 (enExample)
EP (1) EP2713727B1 (enExample)
JP (2) JP6263468B2 (enExample)
CN (1) CN103957709A (enExample)
AR (1) AR086656A1 (enExample)
CA (1) CA2837724C (enExample)
TW (1) TW201316991A (enExample)
UY (1) UY34114A (enExample)
WO (1) WO2012167247A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PH12019502809B1 (en) 2012-06-13 2024-04-24 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
CN103408551B (zh) * 2013-07-25 2015-08-05 苏州明锐医药科技有限公司 阿立塞替的制备方法
CN103408552B (zh) * 2013-07-25 2015-07-01 苏州明锐医药科技有限公司 阿立塞替的制备方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3324976A4 (en) * 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Fgfr阻害剤の塩
CN112867716B (zh) 2018-05-04 2024-09-13 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
JP7253181B2 (ja) * 2018-12-21 2023-04-06 株式会社Nttドコモ 情報処理装置、情報処理方法及びプログラム
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021172582A1 (ja) * 2020-02-27 2021-09-02 国立大学法人北海道大学 抗がん剤をスクリーニングする方法及び膵がんの治療のためのキナーゼ阻害剤の組み合わせ医薬
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
JP2024522188A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52436B (sr) 2004-05-14 2013-02-28 Millennium Pharmaceuticals Inc. Jedinjenja i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze
CN101014603B (zh) * 2004-05-14 2014-08-20 千禧药品公司 通过抑制极光激酶抑制有丝分裂的化合物和方法
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
CN101896227A (zh) * 2007-12-12 2010-11-24 阿斯利康(瑞典)有限公司 包含mek抑制剂和极光激酶抑制剂的组合
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
EP2358679A2 (en) 2008-11-18 2011-08-24 Takeda Pharmaceutical Company Limited Process for making (r) - 3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido [2,3-d] pyrimidine-4,7 (3h,8h)-dione and intermediates thereof
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
WO2011103089A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate

Also Published As

Publication number Publication date
EP2713727A4 (en) 2014-10-22
WO2012167247A1 (en) 2012-12-06
JP2017178969A (ja) 2017-10-05
TW201316991A (zh) 2013-05-01
CA2837724A1 (en) 2012-12-06
CN103957709A (zh) 2014-07-30
US20140336180A1 (en) 2014-11-13
JP2014516992A (ja) 2014-07-17
AR086656A1 (es) 2014-01-15
US9629850B2 (en) 2017-04-25
CA2837724C (en) 2019-10-29
EP2713727A1 (en) 2014-04-09
JP6263468B2 (ja) 2018-01-17
EP2713727B1 (en) 2021-03-31

Similar Documents

Publication Publication Date Title
UY34114A (es) Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
UY34045A (es) Derivados de imidazopiridina como inhibidores de pi3k
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34146A (es) Compuestos inhibidores de metaloenzimas
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34550A (es) Bencilpirazoles sustituidos
UY33930A (es) Inhibidores novedosos de quinasas
UY34523A (es) Derivados de betulina
UY34538A (es) Heteroarilos y usos de los mismos
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34374A (es) Benzilindazoles sustituidos
UY4175Q (es) Reloj pulsera
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34092A (es) Nuevos compuestos como inhibidores de jak
UY34138A (es) Antagonistas de trpv4
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
UY34654A (es) Inhibidores de la beta-secretasa
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY34057A (es) Inhibidores del virus de la hepatitis c
UY34034A (es) Triazolopiridinas
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20210915